TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preferred Components: The bioactive compound comprises a polynucleotide of interest or a polypeptide of interest. The polynucleotide of interest comprises a silencing element, where expression or introduction of the silencing element into a cell reduces the expression of a target polynucleotide or the polypeptide encoded thereby. The silencing element comprises an interfering RNA. The interfering RNA comprises siRNA.    TECHNOLOGY FOCUS - INORGANIC CHEMISTRY - Preferred Components: The biodegradable ionic precipitate is a calcium phosphate precipitate.    TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred Components: The lipid-PEG conjugate comprises PEG in an amount of 12-50 mol.% of total surface lipid. The lipid-PEG conjugate comprises a PEG molecule having a molecular weight of 2000 g/mol. The lipid-PEG conjugate comprises a 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-carboxy- polyethylene glycol2000 (DSPE-PEG2000). The cationic lipid is N-(2,3-dioleoyloxy) propyl)-N,N,N-trimethylammonium chloride (DOTAP).    TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Complex: In the delivery system complex, the liposome comprises a lipid bilayer having an inner leaflet and an outer leaflet, and where the outer leaflet comprises a lipid-polyethylene glycol (lipid-PEG) conjugate. The delivery system complex comprises a biodegradable ionic precipitate containing a bioactive compound surrounded by a lipid bilayer containing an inner and an outer leaflet, where the biodegradable ionic precipitate is ionically bound to the inner leaflet of the lipid bilayer. In the delivery system complex, the outer leaflet comprises a targeting ligand, thereby forming a targeted delivery system complex, where the targeting ligand targets the targeted delivery system complex to a targeted cell. In the delivery system complex, the outer leaflet comprises a cationic lipid. Preferred Method: The method of making the delivery system complex involves: mixing a first reverse microemulsion comprising calcium chloride and a second reverse microemulsion containing sodium phosphate and an amphiphilic lipid having a free phosphate group to form a calcium phosphate precipitate, where the bioactive compound is within the first reverse microemulsion or the second reverse microemulsion; washing the calcium phosphate precipitate; solubilizing the calcium phosphate precipitate in a volatile, organic solvent to form a calcium phosphate precipitate/solvent mixture; adding a lipid to the calcium phosphate precipitate/solvent mixture; and evaporating the volatile, organic solvent to produce the delivery system complex. Preferred Components: The bioactive compound comprises a water-soluble bioactive compound. The water-soluble bioactive compound is water-soluble chemotherapeutic drug. The bioactive compound has a phosphate group. ACTIVITY - Cytostatic; Antimicrobial; Cardiovascular-Gen.; Antiinflammatory.    MECHANISM OF ACTION - RNA Interference. The efficacy of delivery system complex (C1) comprising lipid/calcium phosphate (LCP)-II nanoparticle and gemcitabine monophosphate was tested for cytostatic activity by using standard assay on human lung cancer NCI-H460 cells, and IC50 value was evaluated. The complex (C1) showed IC50 value of 5 nM.    ADMINISTRATION - Administration is by parenteral, intravenous, intradermal, subcutaneous, oral, nasal, bronchial, inhalation, ophthalmic, transdermal, topical, transmucosal, rectal, vaginal, intraperitoneal, intramuscular, subdermal, or intracranial route. No dosage details given.    EXAMPLE - Two separate reverse microemulsions containing calcium chloride (CaCl2) and sodium phosphate (Na2HPO4), respectively, were mixed. The microemulsion containing the phosphate was stabilized with an amphiphilic lipid having a free phosphate group, such as the phospholipid dioleoyl phosphatidic acid (DOPA). The calcium chloride microemulsion (pH 7) comprised the siRNA or other water-soluble drug. The pH of the sodium phosphate microemulsion was brought to a pH of 9 through the addition of small amounts of NaOH e.g. When the two microemulsions were combined, a calcium phosphate (CaP) precipitate forms inside the microemulsion. The CaP cores were suspended in excess EtOH and centrifuged to pellet the CaP cores. After extensive washing with EtOH to remove surfactants, the CaP cores were solubilized in a volatile, organic solvent, such as chloroform (CHCl3). Due to the coating with the amphiphilic lipid with the free phosphate group (e.g. DOPA), the CaP cores were soluble in the organic solvent (e.g. CHCl3) and stored under these conditions at 4 degrees C for one month. A lipid was added to the solution and the organic solvent (e.g. CHCl3) was evaporated. The residue was then resuspended in water to obtain lipid/calcium phosphate (LCP)-II nanoparticle preparation which further combined with gemcitabine monophosphate to obtain a delivery system complex.